OpenAI and the US Food and Drug Administration are considering the 'cderGPT' AI project for drug review
OpenAI, known for developing ChatGPT, is reportedly in discussions with the US Food and Drug Administration (FDA) about 'AI for drug review.'
OpenAI and the FDA are reportedly discussing AI for drug evaluations | TechCrunch
The discussions between OpenAI and the FDA are reportedly regarding a project called ' cderGPT .'
The US Food and Drug Administration has a department called the Center for Drug Evaluation and Research (CDER), which is responsible for reviewing over-the-counter and prescription drugs, and the name 'cderGPT' is thought to be taken from CDER.
Center for Drug Evaluation and Research (CDER) | FDA
https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder
It is not uncommon for the drug approval process to take more than 10 years, so it is believed that the purpose of this 'cderGPT' is to accelerate the review portion.
It has been reported that Elon Musk, a member of the Department of Government Efficiency (DOGE), was present at the meeting between OpenAI and the FDA. It is unclear how Musk was involved in the discussion.
By the way, FDA Commissioner Marty McCully said at the American Heart Association (AHA) annual conference that AI will be needed to shorten the drug approval process.
FDA commissioner talks of shortening drug approval process, benefits of AI | AHA News
According to McCully, the FDA intends to conduct its first AI-assisted drug review in the second week of May 2025 and to have the process in place by summer 2025, ultimately shortening the time it takes for drugs to be approved.
Related Posts:
in Note, Posted by logc_nt